In addition, increased EGFR levels were detected in the lung tissue of SARS-CoV-2 deceased individuals (e.g., type I and type II pneumocytes, alveolar macrophages, and fibroblasts), and EGFR was identified as a key regulator of fibrosis in COVID-19 (Vagapova et al, 2021) suggesting the use of anti-EGFR antibodies to reduce inflammation and lung fibrosis in severe COVID-19 patients (Londres et al, 2022). Here, EGFR is linked to pulmonary fibrosis.